重大事件
即時報告
8-K
2026-06-23
MiNK Therapeutics年度股東大會通過董事選舉及委任KPMG為核數師
AI 繁中摘要
MiNK Therapeutics, Inc. 於 2026 年 6 月 17 日舉行年度股東大會，並於會後提交 8-K 申報。會上共有 3,277,906 股普通股（佔已發行及合資格投票股份的 65.79%）親身或經由有效委託書出席，達成法定人數。
兩項議案均獲通過 📊：
✅ 議案一：選舉三名二類董事，任期三年至 2029 年股東大會。投票結果如下：
- Garo Armen：贊成 2,363,360 票，反對 0 票，棄權 32,898 票，經紀人未投票 881,648 票
- Barbara Ryan：贊成 2,362,760 票，反對 0 票，棄權 33,498 票，經紀人未投票 881,648 票
- John Holcomb：贊成 2,381,491 票，反對 0 票，棄權 14,767 票，經紀人未投票 881,648 票
✅ 議案二：批准委任 KPMG LLP 為公司截至 2026 年 12 月 31 日止財政年度的獨立註冊會計師事務所。投票結果：贊成 3,249,124 票，反對 26,560 票，棄權 2,222 票，無經紀人未投票。
是次會議結果反映股東對現有管理層及審計安排的支持，公司治理結構保持穩定，對投資者而言屬正面訊息 🎯。
展開英文正文
8-K 0001840229false00018402292026-06-172026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2026 MiNK Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40908 82-2142067 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 149 Fifth Avenue Suite 500 New York, New York 10010 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: 212 994-8250 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.00001 per share INKT The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 17, 2026. A total of 3,277,906 shares of common stock, representing 65.79% of the shares outstanding and eligible to vote and constituting a quorum, were present at the Annual Meeting or represented by valid proxies. At the Annual Meeting, the Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2026: (i) to elect Garo Armen, Barbara Ryan and John Holcomb as Class II Directors, each for a term of three years expiring at the 2029 Annual Meeting of Stockholders (“Proposal 1”), (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”). The Company’s stockholders elected each of the Class II Director nominees nominated for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for the Class II Directors as follow: Class II Director Nominees For Against Withheld Broker Non-Votes Garo Armen 2,363,360 0 32,898 881,648 Barbara Ryan 2,362,760 0 33,498 881,648 John Holcomb 2,381,491 0 14,767 881,648 The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 3,249,124 26,560 2,222 0 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 23, 2026 By: /s/ Jennifer S. Buell, Ph.D. Jennifer S. Buell, Ph.D. President and CEO